Pancreatic exocrine insufficiency in cystic fibrosis is genetically determined and generally felt to be irreversible. However, recent studies in young children started on cystic fibrosis transmembrane conductance regulator (CFTR) modulators have suggested improvement of pancreatic functioning over time. Here, we present the case of a 10-year-old child with pancreatic exocrine insufficiency since birth who regained pancreatic functioning after 4 years on the CFTR corrector drug, ivacaftor.
No takes yet. Share an insight, caveat, or question.
Megalaa et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context:
More from Pediatric Pulmonology